143 related articles for article (PubMed ID: 38048735)
1. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
[TBL] [Abstract][Full Text] [Related]
2. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
[TBL] [Abstract][Full Text] [Related]
4. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
[TBL] [Abstract][Full Text] [Related]
7. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract][Full Text] [Related]
9. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
10. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract][Full Text] [Related]
11. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
Tao Z; Cui Y; Xu X; Han T
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
[TBL] [Abstract][Full Text] [Related]
12. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver.
Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237
[TBL] [Abstract][Full Text] [Related]
15. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
[TBL] [Abstract][Full Text] [Related]
16. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
Xie H; Alem Glison DM; Kim RD
Expert Opin Investig Drugs; 2022 Apr; 31(4):393-400. PubMed ID: 34913780
[TBL] [Abstract][Full Text] [Related]
17. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
He Q; Huang W; Liu D; Zhang T; Wang Y; Ji X; Xie M; Sun M; Tian D; Liu M; Xia L
Theranostics; 2021; 11(12):5759-5777. PubMed ID: 33897880
[No Abstract] [Full Text] [Related]
18. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
20. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
